Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
February 28, 2024 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
November 29, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
July 24, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
January 04, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

JUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
December 14, 2022 08:30 ET | Source: Dyadic International, Inc.

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
October 04, 2022 08:45 ET | Source: Dyadic International, Inc.

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
August 10, 2022 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
August 09, 2022 16:48 ET | Source: Bragar Eagel & Squire

GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
June 28, 2021 08:30 ET | Source: Dyadic International, Inc.

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...

Next Page keyboard_arrow_right